1.
Adwan L, Subaiea GM, Basha R, Zawia NH. Tolfenamic acid reduces tau
and CDK5 levels: Implications for dementia and tauopathies. Journal of
Neurochemistry. 2015 133(2):266-72. IF 4.244

2.
Subaiea GM, Ahmed AH, Adwan LI, Zawia NH. Reduction of amyloid-beta deposition and attenuation of memory deficits by tolfenamic acid.
Journal of Alzheimer's Disease. 2015 43(2):425-33. IF 3.612                                                                                          

3.
Adwan L, Subaiea GM, Zawia NH. Tolfenamic acid downregulates BACE1
and protects against lead-induced upregulation of Alzheimer's disease related biomarkers. Neuropharmacology. 2014 79:596-62. IF 4.819                                                                       

4.
Subaiea GM, Adwan LI, Ahmed AH, Stevens KE, Zawia NH. Short-term
treatment with tolfenamic acid improves cognitive functions in Alzheimer's
disease mice. Neurobiology of Aging. 2013 34(10):2421-30. IF
4.853                                                              

5.
Sankpal UT, Lee CM, Connelly SF, Kayaleh O, Eslin D, Sutphin R, Goodison S, Adwan
L, Zawia NH, Lichtenberger LM, Basha R. Cellular and
organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a
pre-clinical evaluation. Cellular Physiology and Biochemistry. 2013 32(3):675-86.
IF 3.55

6. Adwan
LI, Zawia NH. Epigenetics: A novel therapeutic approach for the
treatment of Alzheimer’s disease. Pharmacology and Therapeutics.
2013 139(1):41-50. IF 8.562

7. Adwan
LI, Basha R, Abdelrahim M, Subaiea GM, Zawia NH. Tolfenamic acid
interrupts the de novo synthesis of the beta-amyloid precursor protein and lowers
amyloid beta via a transcriptional pathway. Current Alzheimer Research.
2011 8(4):385-92. IF 3.953             

8. Dosunmu
R, Wu J, Adwan L, Maloney B, Basha MR, McPherson CA, Harry GJ, Rice DC,
Zawia NH, Lahiri DK. Lifespan profiles of Alzheimer's disease-associated
genes and products in monkeys and mice. Journal of Alzheimer's Disease.
2009 18(1):211-30. IF 3.612